Talha Badar: DDX41mt predisposition syndrome in myeloid neoplasms / cancer, DDX41mt, myeloid neoplasms, OncoDaily, Oncology, Talha Badar

npj Precision Oncology - Delta-like ligand 3 (DLL3) landscape in pulmonary and extra-pulmonary neuroendocrine neoplasms

Number of deaths caused by neoplasms, by age group and sex, 2000 to most recent year.

Buy a cheap copy of Homo Ecophagus book by Warren M. Hern. Home Ecophagus by Warren M. Hern is a wide-ranging look at the major problems for the survival of not just the human species, but all other s...

Learn about neoplasms, including benign and malignant tumors, genetic mutations, BRCA-related cancer risks, and how abnormal cell growth leads to cancer.

Shernan Holtan: A signal of protection from myeloid neoplasms by GLP-1RA / Abhay Singh, Ali Mushtaq, cancer, David Kaelber, Faiz Anwer, GLP-1 Receptor

Patient Advocacy

Classical myeloproliferative neoplasms (MPNs) are being identified more frequently in adolescents. There is no guidance on the healthcare transition of young MPN patients from pediatric to adult medi...

Histiocytic neoplasms are clonal disorders of the monocyte/macrophage lineage defined by mutations activating mitogen-activated protein kinase (MAPK) …

Lung neuroendocrine neoplasms are a group of diverse, heterogeneous tumours that range from well-differentiated, low-grade neuroendocrine tumours—such as typical and atypical carcinoids—to high-grade, poorly differentiated aggressive malignancies, such as large-cell neuroendocrine carcinoma (LCNEC) and small-cell lung cancer (SCLC). While the incidence of SCLC has decreased, the worldwide incidence of other pulmonary neuroendocrine neoplasms has been increasing over the past decades. In addition to the standard histopathological classification of lung neuroendocrine neoplasms, the introduction of molecular and sequencing techniques has led to new advances in understanding the biology of these diseases and might influence future classifications and staging that can subsequently improve management guidelines in the adjuvant or metastatic settings.

Key PointsGerm line variants stratify t-MN into molecularly and prognostically distinct subgroups beyond treatment-based classifications.CT exposure drives